, Volume 161, Issue 2, pp 143–151 | Cite as

Treatment strategies in patients with major depression not responding to first-line sertraline treatment

A randomised study of extended duration of treatment, dose increase or mianserin augmentation
  • Rasmus W. Licht
  • Susanne Qvitzau
Original Investigation


Rationale: A large proportion of patients with major depression do not respond sufficiently to any first-line treatment. Objectives: The aim of this study was to compare a strategy of sertraline dose increase with a strategy of adding mianserin in patients with major depression insufficiently responding to 6 weeks of open treatment with sertraline, controlling for the effect of an extended duration of treatment. Methods: One thousand six hundred and twenty-nine patients, 18–65 years of age, with major depression scoring at least 18 on the 17-item Hamilton depression scale (HDS) were treated openly with 50 mg/day sertraline, and patients who after 4 weeks had not responded (achieving at least a 50% reduction in score on the HDS) were treated with 100 mg/day sertraline for an additional 2-week period. The patients who had still not responded were then randomised to double-blind treatment for an additional 5 weeks with either 100 mg/day sertraline plus placebo, 200 mg/day sertraline plus placebo or 100 mg/day sertraline plus 30 mg/day mianserin. Results: After 6 weeks of open treatment, 60% had responded and 22% had dropped out, leaving 295 non-responding patients (18%) for randomisation. In the intention-to-treat-analysis, continuing the treatment with 100 mg/day sertraline resulted in response in 70% of the non-responders, similar to the response rate (67%) obtained in the patients who had mianserin added. However, increasing the sertraline dose to 200 mg/day resulted in a lower response rate at 56% (P<0.05). Similar results were seen in the completers. A substantial increase in the accumulated response rate from week 6 to week 8 was seen. There was no influence of baseline variables, including the presence of melancholic features on the overall post-randomisation response rate. Conclusion: After 6 weeks of insufficient antidepressant treatment with 50–100 mg/day sertraline, a continued treatment with 100 mg/day sertraline can be considered until at least week 8 before considering changing strategy, unless the condition deteriorates.

Drug combination Depressive disorder Mianserin Placebo Randomised controlled trial Sertraline Drug therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  • Rasmus W. Licht
    • 1
  • Susanne Qvitzau
    • 2
  1. 1.Mood Disorders Research Unit, Aarhus University Psychiatric Hospital, 8240 Risskov, Denmark
  2. 2.Pfizer A/S, Copenhagen, Denmark

Personalised recommendations